The short version of LC-MS/MS fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-03-08 and is reviewed periodically as new material appears.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
=== Wound cleansing === Dirt or dust on the surface of the wound, bacteria, tissue that has died, and fluid from the wound may be cleaned. The evidence supporting the most effective technique is not clear and there is insufficient evidence to conclude whether cleaning wounds is beneficial for promoting healing or whether wound cleaning solutions (polyhexamethylene biguanide, aqueous hydrogen peroxide, etc.) are better than sterile water or saline solutions to help venous leg ulcers heal. It is uncertain whether the choice of cleaning solution or method of application makes any difference to venous leg ulcer healing.
=== Radiometric dating === Two radiometric dating methods involve thorium isotopes: uranium–thorium dating, based on the decay of 234U to 230Th, and ionium–thorium dating, which measures the ratio of 232Th to 230Th. These rely on the fact that 232Th is a primordial radioisotope, but 230Th only occurs as an intermediate decay product in the decay chain of 238U. Uranium–thorium dating is a relatively short-range process because of the short half-lives of 234U and 230Th relative to the age of the Earth: it is also accompanied by a sister process involving the alpha decay of 235U into 231Th, which very quickly becomes the longer-lived 231Pa, and this process is often used to check the results of uranium–thorium dating. Uranium–thorium dating is commonly used to determine the age of calcium carbonate materials such as speleothem or coral, because uranium is more soluble in water than thorium and protactinium, which are selectively precipitated into ocean-floor sediments, where their ratios are measured. The scheme has a range of several hundred thousand years. Ionium–thorium dating is a related process, which exploits the insolubility of thorium (both 232Th and 230Th) and thus its presence in ocean sediments to date these sediments by measuring the ratio of 232Th to 230Th. Both of these dating methods assume that the proportion of 230Th to 232Th is a constant during the period when the sediment layer was formed, that the sediment did not already contain thorium before contributions from the decay of uranium, and that the thorium cannot migrate within the sediment layer.
Pramlintide (trade name Symlin) is an injectable amylin analogue drug for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals (now a wholly owned subsidiary of AstraZeneca). Pramlintide is sold as an acetate salt.
=== 2017 === The "Duty to Warn" movement was founded by medical professionals concerned about Trump's cognitive health in his first year in office. In 2016 and 2017, a number of psychiatrists and clinical psychologists faced criticism for violating the Goldwater rule; despite having never examined him, they maintained that Donald Trump displayed "an assortment of personality problems, including grandiosity, a lack of empathy, and 'malignant narcissism'", and that he had a "dangerous mental illness". In 2017, psychologist John Gartner collected more than 41,000 signatures of mental health professionals on a petition, directed to then-Senate Minority Leader Chuck Schumer. The petition asserted that Trump suffered from a serious mental illness and was "psychologically incapable of competently discharging the duties" of the presidency. Gartner asserted that Trump's mental handicaps are a mix of narcissism, paranoia, sociopathy, and sadism. In February 2017, psychiatrist Allen Frances wrote a letter to the editor of The New York Times regarding Trump and narcissistic personality disorder. Frances said, "I wrote the criteria that define this disorder, and Mr. Trump doesn't meet them." According to the American Psychiatric Association, "saying that a person does not have an illness is also a professional opinion." On April 14, 2017, Representatives Jamie Raskin and Earl Blumenauer introduced the Oversight Commission on Presidential Capacity Act.
The skin is the largest organ of the human body that restricts the movement of drug to the systemic circulation. The topical drug delivery system is a system where the drug reaches the systemic circulation through the protective skin layer. The main disadvantage of this route is the low diffusion rate of the drugs across the layer of skin which is the stratum corneum. To overcome this problem to a certain extent, ethosomes are used to enhance transdermal drug delivery systems.
Sources: en.wikipedia.org
=== Comic Books === Comics published during the Cold War provided both entertainment and political commentary. Themes of foreign wars, radiation, and social injustices were prevalent within the genre. Comics like Fantastic Four show American's relationship to the nuclear family unit, while other comics like Spider-Man and The Incredible Hulk show societal fears related to nuclear power and its effects. Other comics were less focused on fantastical elements and instead set their stories within Cold War events. Marines In Action was a comic series that ran from 1955 to 1957 that focuses on fictional characters within the Korean War. These comics were pro-war, which was a common sentiment among military centered stories.Golgo 13, a Japanese comic published since October 1968 also portrayed Cold War events like Fall of the Berlin Wall and Tiananmen Square protests from the perspective of the protagonist, a professional hitman hired by different powers.
The 2025 summit was the first summit for European Council President António Costa, British prime minister Keir Starmer, Canadian prime minister Mark Carney, and German chancellor Friedrich Merz. It was also the first and only summit for Japanese prime minister Shigeru Ishiba. The visit marked the first international visit to Canada for British prime minister Keir Starmer, Japanese prime minister Shigeru Ishiba, German chancellor Friedrich Merz, Australian prime minister Anthony Albanese, South Korean president Lee Jae Myung, and marked the second visit to Canada by Italian prime minister Giorgia Meloni and US president Donald Trump and the first visit since the 44th G7 summit in 2018. It marked the third visit to Canada for French president Emmanuel Macron and Ukrainian president Volodymyr Zelenskyy. In May, Mexican president Claudia Sheinbaum was invited to attend. Following the announcement, she told reporters that she had not decided if she would attend, but that it is "a possibility". On 30 May, Brazilian president Luiz Inácio Lula da Silva was invited and is expected to attend. In June, Crown Prince of Saudi Arabia Mohammed bin Salman was invited. However, on 12 June it was confirmed that he will not be attending the summit. Indonesian president Prabowo Subianto was initially invited by Mark Carney to attend the G7 summit, which he accepted. However, on 12 June, Prabowo announced that he would skip the summit and meet Singaporean prime minister Lawrence Wong, Vietnamese president Lương Cường, and Russian president Vladimir Putin instead.
== Safety == There hasn't been extensive research conducted on the safety of sandalwood oil. But because there haven't been any significant adverse effects documented in scientific literature, it continues to be used cosmetically and in food. A few studies were found to identify sandalwood oil's potential toxic effects, but it was determined to be safe at the present levels that the oil is used in food as flavorings.
Diets low in whole grains are the leading concern (18 percent of global quantified health hidden costs), alongside diets high in sodium and low in fruits (16 percent each), although there is significant variation across countries.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.